Pregabalin Shortage: What Providers and Prescribers Need to Know in 2026

Pregabalin remains one of the most widely prescribed medications in the United States, indicated for neuropathic pain, fibromyalgia, and adjunctive treatment of partial-onset seizures. While the drug is not currently in a formal FDA-declared shortage, clinicians across multiple specialties continue to encounter patients who report difficulty filling their prescriptions. This briefing provides an up-to-date overview of the supply landscape and practical guidance for prescribers managing affected patients.

Current Supply Status

As of early 2026, pregabalin does not appear on the FDA Drug Shortage Database. The introduction of generic pregabalin in 2019 significantly expanded manufacturing capacity, and multiple manufacturers now supply the US market. This multi-source supply provides resilience that brand-name-only medications lack.

Despite this, prescribers should be aware that pharmacy-level stock variability is real and patient-reported. Factors contributing to localized availability challenges include:

• Schedule V regulatory overhead: Pharmacies must comply with DEA ordering rules and state PDMP reporting for pregabalin. This can extend restocking timelines relative to non-scheduled drugs.
• Strength fragmentation: Pregabalin is dispensed in 8 capsule strengths (25–300 mg), an oral solution, and extended-release tablets. Pharmacy stock-outs often affect specific strengths, not the entire drug.
• Generic manufacturer variability: Individual pharmacies source from specific wholesalers. If one supplier is backordered on a particular strength, the pharmacy may not automatically switch to an alternative manufacturer's product without a prompt.
• High cross-specialty demand: Neurologists, pain specialists, rheumatologists, psychiatrists, and primary care physicians all prescribe pregabalin. Compounding demand from multiple specialties can strain individual pharmacy inventories.

Controlled Substance Considerations for Prescribers

Pregabalin is classified as a DEA Schedule V controlled substance — the lowest federal schedule — due to reports of euphoria in approximately 4% of clinical trial participants and a mild dependence profile. Clinically relevant Schedule V implications include:

• Prescriptions may be phoned, faxed, or e-prescribed in most states (check your state's specific requirements)
• State PDMP review prior to prescribing is required in most states — check your state's mandate
• Telehealth prescribing of pregabalin remains permissible under current DEA flexibilities, which have been extended through December 31, 2026 (fourth temporary extension)
• Caution is warranted in patients with history of substance use disorder; review PDMP before prescribing and consider risk-benefit assessment

Critical Safety Alert: Abrupt Discontinuation Risk

When patients cannot fill their prescription, abrupt discontinuation is a significant risk. Withdrawal symptoms from pregabalin may include insomnia, headache, nausea, anxiety, diarrhea, flu-like symptoms, and in severe cases, seizures — even in patients not using pregabalin for seizure control. The FDA-approved label recommends tapering over a minimum of one week; many guidelines recommend a slower taper for long-term users.

Clinicians should proactively counsel patients to contact the practice early if they encounter difficulty filling a prescription — before they run out — rather than after. Consider providing a brief supply of samples if available, or a bridge prescription at an alternative pharmacy, when pharmacy-level shortages are anticipated.

Prescribing Strategies When Specific Strengths Are Unavailable

If a patient's prescribed strength is temporarily unavailable, consider the following approaches:

1. Equivalent-dose reformulation: Pregabalin capsules can often be combined to achieve an equivalent total daily dose. For example, if 150 mg capsules are unavailable, two 75 mg capsules can be prescribed per dose. Confirm with the pharmacist that the alternative strength is available before writing the prescription.
2. Oral solution: The 20 mg/mL oral solution allows highly flexible dosing and may be available when capsules of a specific strength are not. This is especially relevant for pediatric patients or those with swallowing difficulties.
3. Direct pharmacy call: Prescribers or office staff calling pharmacies directly on a patient's behalf can sometimes facilitate faster resolution than patient self-navigation, particularly in practices with established pharmacy relationships.

Therapeutic Alternatives When Pregabalin Is Genuinely Unavailable

For patients who cannot access pregabalin for an extended period, consider these alternatives — noting that each has different indications, evidence, and risk profiles:

• Gabapentin: Same mechanism of action, not federally scheduled, less expensive. Requires TID dosing and dose titration. Not FDA-approved for fibromyalgia.
• Duloxetine: FDA-approved for diabetic peripheral neuropathy and fibromyalgia. SNRI mechanism, not a controlled substance. May be preferred when comorbid depression/anxiety is present. Not appropriate for seizure management.
• Amitriptyline: Low-dose TCA for neuropathic pain. Anticholinergic effects limit use in older adults and those with cardiovascular comorbidities. Not appropriate for seizure management.
• For seizure management: Consult neurology before substituting any antiepileptic. Precipitous changes in AED regimen can trigger breakthrough seizures.

A Tool for Your Patients: medfinder

When patients encounter difficulty filling pregabalin, the primary bottleneck is often pharmacy navigation — not a genuine supply problem. Directing patients to medfinder for providers can help. medfinder contacts pharmacies in the patient's area to identify which ones have the specific medication and strength in stock, then texts the patient with results. This can reduce the time between prescription issuance and successful fill, and decrease the likelihood of abrupt discontinuation due to inability to locate the drug.

For a step-by-step guide on helping patients find pregabalin in stock, see our companion article: How to Help Your Patients Find Pregabalin in Stock: A Provider's Guide.